

# MDisrupt Financial Projections (2024-2027)

	Q1 - 2024	Q2 - 2024	Q3 - 2024	Q4 - 2024 (P)
Marketplace Revenue	\$ 301,970	\$ 291,062	\$ 174,820	\$ 494,750
Subscription Revenue	\$ 80,423	\$ 81,652	\$ 50,326	\$ 42,952
Special Projects Revenue	\$ -	\$ -	\$ -	\$ -
<b>Total Revenue</b>	<b>\$ 382,393</b>	<b>\$ 372,713</b>	<b>\$ 225,145</b>	<b>\$ 537,702</b>
Experts Cost of Services	\$ 224,624	\$ 170,673	\$ 100,552	\$ 327,899
Credit Expert Costs	\$ 10,000	\$ 27,625	\$ 6,200	\$ -
Special Projects Cost of Services	\$ -	\$ -	\$ -	\$ -
<b>Cost of Sales</b>	<b>\$ 234,624</b>	<b>\$ 198,298</b>	<b>\$ 106,752</b>	<b>\$ 327,899</b>
<b>Net Revenue</b>	<b>\$ 147,769</b>	<b>\$ 174,416</b>	<b>\$ 118,393</b>	<b>\$ 209,803</b>
Total GM %	38.64%	46.80%	52.59%	39.02%
Clinical	\$ 3,889	\$ -	\$ -	\$ -
Sales & Marketing	\$ 122,684	\$ 114,214	\$ 105,654	\$ 185,455
Research & Development	\$ 123,183	\$ 96,375	\$ 106,562	\$ 196,968
General & Administrative	\$ 252,979	\$ 237,476	\$ 222,721	\$ 470,609
<b>Total Operating Expenses</b>	<b>\$ 502,735</b>	<b>\$ 448,065</b>	<b>\$ 434,937</b>	<b>\$ 853,031</b>
<b>Operating Income (EBITDA)</b>	<b>\$ (354,966)</b>	<b>\$ (273,649)</b>	<b>\$ (316,544)</b>	<b>\$ (643,228)</b>
EBITDA %	-92.83%	-73.42%	-140.60%	-119.63%
Net Other	\$ 118,243	\$ 243	\$ 281,585	\$ -
<b>Net Income</b>	<b>\$ (236,723)</b>	<b>\$ (273,406)</b>	<b>\$ (34,958)</b>	<b>\$ (643,228)</b>

2024 (P)	2025 (P)	2026 (P)	2027 (P)
\$ 1,262,601	\$ 4,164,000	\$ 9,213,500	\$ 18,453,000
\$ 255,352	\$ 312,910	\$ 535,011	\$ 655,011
\$ -	\$ -	\$ -	\$ -
<b>\$ 1,517,953</b>	<b>\$ 4,476,910</b>	<b>\$ 9,748,511</b>	<b>\$ 19,108,011</b>
\$ 823,747	\$ 2,594,880	\$ 5,942,520	\$ 12,594,960
\$ 43,825	\$ 4,750	\$ 4,997	\$ 59,667
\$ -	\$ -	\$ -	\$ -
<b>\$ 867,572</b>	<b>\$ 2,599,630</b>	<b>\$ 5,947,517</b>	<b>\$ 12,654,627</b>
<b>\$ 650,381</b>	<b>\$ 1,877,280</b>	<b>\$ 3,800,994</b>	<b>\$ 6,453,384</b>
42.85%	41.93%	38.99%	33.77%
\$ 3,889	\$ -	\$ -	\$ -
\$ 528,007	\$ 1,092,903	\$ 1,495,341	\$ 1,880,885
\$ 523,087	\$ 1,039,496	\$ 1,431,982	\$ 1,796,839
\$ 1,183,785	\$ 2,000,361	\$ 2,208,142	\$ 2,500,159
<b>\$ 2,238,768</b>	<b>\$ 4,132,760</b>	<b>\$ 5,135,465</b>	<b>\$ 6,177,883</b>
<b>\$ (1,588,388)</b>	<b>\$ (2,255,479)</b>	<b>\$ (1,334,471)</b>	<b>\$ 275,501</b>
-104.64%	-50.38%	-13.69%	1.44%
\$ 400,072	\$ -	\$ -	\$ -
<b>\$ (1,188,316)</b>	<b>\$ (2,255,479)</b>	<b>\$ (1,334,471)</b>	<b>\$ 275,501</b>

**The current model on the previous slide is a conservative estimate of our base business as we know it today.**

However there are additional upside opportunities that are currently not included in the model:

- Experts paying subscriptions for premium features
- Enterprise level subscriptions for
  - Investors, Incubators, Studios
  - Large Medtech and Life Sciences Companies
- New products and platform features beyond those on our current roadmap
- Licensing deals